Last update 01 Nov 2024

Mengyang Pharmaceutical (Shanghai) Co., Ltd.

Private Company|
2020|
Shanghai Shi, China

Overview

Tags

Neoplasms
Cardiovascular Diseases
Other Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
no Data
No Data
Disease DomainCount
Neoplasms1
Top 5 Drug TypeCount
Small molecule drug1

Related

1
Drugs associated with Mengyang Pharmaceutical (Shanghai) Co., Ltd.
DH-001
Target-
Mechanism-
Active Org.
Zhejiang Dinghui Medical Technology Co., Ltd.Zhejiang Dinghui Medical Technology Co., Ltd. [+1]
Originator Org.
Zhejiang Dinghui Medical Technology Co., Ltd.Zhejiang Dinghui Medical Technology Co., Ltd.
Active Indication
Neoplasms [+1]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Mengyang Pharmaceutical (Shanghai) Co., Ltd.
NCT06092606 / RecruitingPhase 2
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
100 Clinical Results associated with Mengyang Pharmaceutical (Shanghai) Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Mengyang Pharmaceutical (Shanghai) Co., Ltd.
Login to view more data
100 Deals associated with Mengyang Pharmaceutical (Shanghai) Co., Ltd.
Login to view more data
100 Translational Medicine associated with Mengyang Pharmaceutical (Shanghai) Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
DH-001
Cardiotoxicity drug-induced
More
Phase 2
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free